首页> The cancer journal> Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.

导出原文传递

翻译打印收藏纠错

第一作者： Olmos D

作者： Olmos D ^[1] ; Tan DS ; Jones RL ; Judson IR

作者单位： Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom. ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The cancer journal

2010年16卷3期

183-194页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

The cancer journal

2010年16卷3期

183-194页

检索历史清除

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.

The cancer journal

相似文献

同项目论文

The cancer journal

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.

The cancer journal

相似文献

同项目论文

The cancer journal

相关期刊

检索历史清除